Vnr. Nordic Article Number. Instruction booklet Version: 1.7 1/23

Similar documents
Nordic Instructions for Nordic Article Numbers (Vnrs) Supplementary information Norway. 1. The flow of article information

Nordic Instructions for Nordic Article Numbers (Vnrs) Supplementary information Norway. 1. The flow of article information

New product code functionality starting Multiple product codes for each article number

Recommendations on a harmonised implementation of the EU Falsified Medicines Directive using GS1 standards

Verification of Pharmaceutical Products at the Point of Dispense. Status of the EFPIA Project

Action plan: serialisation of Nordic packages focus on Product Codes

Drug distribution in hospitals and barcoding. The needs of traceability of medicines in hospitals

Position paper on the identification of the primary package level of drugs

European Union (EU) Falsified Medicines Directive

GS1 Healthcare GTIN Allocation Rules

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4

The European Stakeholder Model A Medicines Verification System for Europe (ESM)

Top 15 Questions and Answers. EU FMD Safety Features and Verification

MHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents

Inside EU FMD and the Delegated Acts A Compliance Primer

Reporting serialized packs in the Vnr Service GTIN and Vnr. Fimvo Essi Kariaho

Mass Serialization and Traceability Implementation in the Pharma Industry. Mathieu Aman, Global Program Lead F. Hoffmann-La Roche Ltd, Switzerland

Verification of Pharmaceutical Products at the Point of Dispense. An EFPIA update

EU Falsified Medicines Directive. Gareth Jones

Implementation manual for barcoding using GS1 global standards for tracking and tracing of pharmaceuticals and drugs for exports

Medicines Barcoding and Serialization Guideline. National Health Regulatory Authority (NHRA) Kingdom of Bahrain

Guidelines for the Serialisation of Medicinal Products

Healthcare. Frequently Asked Questions (FAQs) by the Pharmaceutical Industry in Preparing for the U.S. DSCSA

GS1 Healthcare - Discussion paper on multi-market packs for pharmaceutical products

Official Journal of the European Union. (Non-legislative acts) REGULATIONS

Being Prepared for Track and Trace: DSCSA 101

Experience with Serialization Implementation as one powerful measure to protect our patients. Françoise Hirth

Saudi Drug Code (SDC), and Drug Barcoding Specifications

The FMD Pack Coding, Sharing and Transition

GUIDELINES ON FORMAT AND CONTENT OF LABELS FOR MEDICINAL PRODUCTS

Welcome! 9.30 Medicines Verification System general update Maija Gohlke-Kokkonen, General Manager, FiMVO - Contracting & fees

The Value of Visibility. Bob Celeste GS1 Healthcare US

Frequently Asked Questions Secondary care services and the Falsified Medicines Directive (FMD)

GS1 Ireland Healthcare User Group (HUG) Information Day

Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland

EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update

Serialization Primer

Implementation of EU Falsified Medicines Directive

Guide to Quality Defect Investigation Reports

Background to the Falsified Medicines Directive and the Delegated Regulation. Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016

An analysis of quality product defects in the centralised procedure

Manufacturers serialisation challenges with FMD & DR implementation

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS

Implementation of the safety features in medicinal products for human use

Digital Medicines. FMD in England - Challenges and opportunities in pharmacy

FDA s Bar Code Label Requirements for Human Drug Products. General Questions Related to Drugs and Biologics

Pre-Announcement of Administration of the (Proposed) Legislation of Management Guidelines for Display and Management of Unique Device Identifier

The Danish Generic Medicines Industry Association (IGL)

European Medicines Verification Organisation: Requirements for the European Medicines Verification System URS Lite

Healthcare Demo Scanner 2.0

Guide to Fees for Veterinary Products

Health systems and products Medical products quality, safety and innovation VERSION 8

FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE

1.1 Product(s) registered for sale in Singapore by the Health Sciences Authority (HSA) will be given priority.

HUMAN AND VETERINARY MEDICINES BLOOD AND TISSUE PRODUCTS SUPERVISION OF PHARMACEUTICAL MANUFACTURERS AND WHOLESALERS AND PHARMACIES

Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008

Guide to Parallel Imports of Human Medicines

ICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options

Application for GS1 Malaysia Berhad Membership & LICENSE

Public Assessment Report

Our vision APL

GUIDANCE ON IMPLEMENTATION OF IDENTIFICATION AND BARCODING OF MEDICINAL PRODUCTS FOR HUMAN USE

How to use the defective product report to notify a quality defect to European Medicines Agency

Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products (Therapeutic Products Fees Ordinance)

The Blueprint approach

National Blueprint System Slovakia Kick-Off Meeting

BUSTERSYSTEM. Clinical and Logistics Management of Drugs

Health systems and products Medical products quality, safety and innovation

Belgian Medicines Verification Organisation. End User Implementation

A closer look at the EU- FMD Safety Features Delegated Act: 10 things pharma manufacturers need to consider

Suppliers to the Australian Food Manufacturing Industry

Falsified Medicines Directive (FMD) Leyla Hannbeck MRPharmS, MBA, MSc, MA NPA Chief Pharmacist and Director of Pharmacy

Guideline on the label design for Injections (Draft for Comments)

Standard Terms. Introduction and Guidance for Use. Version January 2018

Application for GS1 Malaysia Berhad Membership & LICENSE

This document provides an overview of the enhancements and support issue fixes in this Minfos release.

Safety Features Required by the Falsified Medicines Directive 2011/62/EU

Global Serialisation Developments and the Need for Convergence. Ulrike Kreysa, Vice-President, GS1 Global Office 3 rd June 2015

Healthcare GTIN Allocation Rules

Romania. Raluca Vasilescu Cabinet M Oproiu. Pharmaceutical Trademarks 2015/2016. A Global Guide

Safety features for medicinal products for human use

Consultation response: Dissolution testing in BP finished products monographs for solid oral dosage forms

APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION

EMEA POST-AUTHORISATION GUIDANCE ON PARALLEL DISTRIBUTION

GS1 Company Prefix Governance

Printing on Tablets & Blister Pouches

Phasing-in EU procedures: MRP and referrals September 23, 2003

General concepts in the Ph. Eur.: theory and rationale

article 25 3 second part* renewal 2267,78 Euro/MAD 1511,86 Euro + (755,93/MAD)

Implementation of the safety features in medicinal products for human use

GMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides

Barcodes on Unit of Use

Falsified Medicines Directive Procedure for managing Alerts generated by the verification system

GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH MICHIGAN STATE UNIVERSITY ENVIRONMENTAL HEALTH AND SAFETY

GS1 standards for unique identification of medicinal products

Opportunities & Challenges with Single Unit Barcoding. Sébastien Langlois-Berthelot

Safety features for medicinal products for human use. Questions & Answers. 1. Document history

APPLICATION FOR MARKETING AUTHORIZATION OF A PHARMACEUTICAL PRODUCT FOR HUMAN USE IN UGANDA

GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET

Transcription:

Vnr Nordic Article Number Instruction booklet Version 1.7 2017-05-10 Version: 1.7 1/23

History Date Version Comment Author 2013-03-25 1.0 New document Hans Andersson 2014-01-22 1.1 Changed names from Apotekens Service Hans Andersson to ehälsomyndigheten. The e-mail address has been changed to registrator@ehalsomyndigheten.se 2014-08-13 1.2 Sentence changed: PIC Vnrs are not needed for sample medicines and products on compassionate use programme, radiopharmaceuticals or, except for Iceland, immunological veterinary medicines 2014-09-09 1.3 Sentence changed: Vnrs are not needed for sample medicines, products on compassionate use programme or for radiopharmaceuticals. In Finland immunological veterinary medicines are also excluded from the Vnr requirement. PIC 2015-10-07 1.4 Country specific information for Iceland added New GTIN/NTIN chapter 8.2 added Contact points updated for PIC 2016-04-05 1.5 4.1 removed sentence A Vnr is only allowed to have the status Assigned for three years. If the Vnr has not been marketed within this time period, the status of the Vnr will be changed to Withdrawn. PIC PIC 8.1.1 Added GS1 links 2016-09-26 1.6 6.4 removed sentence Note that the instructions for Denmark differs from the other Nordic countries, see chapter 10.1.2 Denmark PIC Sections 10.1.2 and 10.1.3 regarding Denmark removed 2017-05-10 1.7 Section 5.7 made clearer and the notification regarding the need of different GTINs added PIC Version: 1.7 2/23

Index Nordic Article Number (Vnr) Instruction booklet 5 1 Nordic Article Number (Vnr) 6 1.1 National article number 6 2 Nordic Number Centre (NNC) 7 3 Application for Nordic Article Number 8 4 Vnr status administration 9 4.1 Assigned 9 4.2 On market 9 4.3 Withdrawn 9 5 Criteria for Nordic Article Number (Vnr) 10 5.1 Trade name 10 5.2 Marketing authorisation holder (MAH) 10 5.3 Pharmaceutical dosage form 11 5.4 Strength 11 5.5 Pack size 11 5.6 Type of package 11 5.7 Package appearance and/or package information leaflet 11 6 Impact on Vnr when an article and/or package is changed 13 6.1 Introduction of a new pharmaceutical product to the market 13 6.2 Change in the composition of the article 13 6.3 Change of trade name 14 6.4 Change of marketing authorisation holder (MAH) 14 6.5 Change of the marketer 14 6.6 Change of pharmaceutical dosage form 15 6.7 Change of strength 15 6.8 Change of pack size 15 6.9 Change of package type 15 6.10 Change of Rx / OTC 15 6.10.1 Switch Rx -> OTC 15 6.10.2 Switch OTC -> Rx 15 6.11 Withdrawal of a Vnr 16 Version: 1.7 3/23

7 Frequently Asked Questions 17 7.1 May a Vnr, if it is already in use in one or several other Nordic countries, automatically be taken into use in another country? 17 7.2 May a medical device have a Nordic Article Number? 17 7.3 May a compounded drug provided under special licence have a Vnr? 17 7.4 May an identical parallel imported article originating from different export countries have the same Vnr in a country and in different countries? 17 7.5 Transport packages and primary packages 17 8 Barcode 18 8.1 Format of the barcode 18 8.1.1 GTIN 18 8.1.2 NTIN 197 8.2 Transfer from NTIN to GTIN 17 9 Multi packages 20 9.1 The single packages of a multi package have market authorisation 20 9.2 Only the multi package has a market authorisation 20 10 Differences between the Nordic countries regarding Vnr 21 10.1 Denmark 21 10.1.1 Change of trade name 21 10.2 Norway 21 10.2.1 Change of Rx / OTC 21 11 Pricing of Nordic Article Numbers 21 12 Contact information 21 12.1 Denmark 21 12.2 Finland 22 12.3 Iceland 22 12.4 Norway 22 12.5 Sweden 22 13 Definitions 23 Version: 1.7 4/23

Nordic Article Number (Vnr) Instruction booklet In this document the common Nordic instructions for Vnrs are described. In addition to the Nordic instructions, there may be additional country specific guidelines, described in separate documents per country. Definitions of keywords are found in chapter 13. Version: 1.7 5/23

1 Nordic Article Number (Vnr) The Nordic Article Number (Vnr) is an identification code for a specific article of medicine with marketing authorisation in the Nordic countries. The Vnr is a six-digit-code (000001-199999 and 370000-599999) given to all human and veterinary medicines. It enables a simple verification of packages at all stages in the drug supply chain from prescription to the patient. Vnrs are not needed for sample medicines, products on compassionate use programme or for radiopharmaceuticals. In Finland immunological veterinary medicines are also excluded from the Vnr requirement. A Vnr can cover one, several, or even all Nordic countries if certain criteria are met, see chapter 5 Criteria for Nordic Article Number. It is extremely important that manufacturers working with products on the market realize that the Vnr is a critical attribute. It functions as an information carrier between a number of IT-systems involved in the prescription, dispensing, ordering, supply, storage and information on medicines. The usage of the Vnr is therefore a matter of well-functioning management of articles as well as patient safety. In addition, electronic prescriptions as well as highly automated management systems in all parts of the distribution chain enhance the risk of fatal consequences if a Vnr is mixed with another Vnr or if it is incorrect in some way. Therefore, all Vnr changes must strictly follow these guidelines for management of Vnrs. The labelling of transport and primary packages falls outside the instructions relating to Nordic article numbering. 1.1 National article number The remaining six-digit-codes (200000-369999 and 600000-999999), which are not Nordic Article Numbers (000001-199999 and 370000-599999), are called National article numbers. They are used differently in the Nordic countries, for instance for consumer products (e.g. shampoo, etc.), medical devices (e.g. blood glucose test strips and colostomy bags), as well as for compounded drugs provided under special licence and extemporaneous preparations. This means that the same National article number is used for different articles in different countries. Version: 1.7 6/23

2 Nordic Number Centre (NNC) The administration of the Vnr system is under responsibility of the Nordic Number Centre (NNC) 1, located at Pharmaceutical Information Centre Ltd (PIC) (Lääketietokeskus Oy), Helsinki, Finland. Each manufacturer with products on the Nordic pharmaceutical market is responsible for informing NNC/PIC of any changes regarding Nordic Article Numbers. Routines for information and cooperation between manufacturers and NNC are specified by NNC, and available through the Vnr extranet service (https://vnr.fi) and e-mail vnr@vnr.fi. 1 On behalf of the Nordic country organisations Dansk Lægemiddel Information A/S in Denmark, Pharmaceutical Information Centre Ltd in Finland, The Icelandic Federation of Trade, Legemiddelindustriforeningen in Norway, and Läkemedelsindustriföreningens Service AB, LIF, in Sweden. Version: 1.7 7/23

3 Application for Nordic Article Number Nordic Article Numbers can be ordered swiftly by using the Vnr extranet service: https://vnr.fi. A user name and a password can be obtained on the website https://vnr.fi. In the Vnr extranet service companies can also see the current information of all their Nordic Article Numbers. The processing time for a Nordic Article Number order, when using the Vnr extranet service, is no more than three working days. Application for a Nordic Article Number should be made when the Marketing Authorisation Holder (MAH) knows which packages will be marketed and really need Vnrs. Technically Vnrs can be applied for at any time. However, a Vnr should be used on the market within three years. Otherwise the status of the Vnr will be changed to Withdrawn, see chapter 4 Vnr status administration. NNC will only provide Vnr information to the owner of the article in question. All other requests for article information will be referred to the National administrators of product- and article information, see chapter 12 Contact information. Vnr information is undisclosed until the marketing authorisation has been approved. Sometimes there is a need to specify for which markets a certain Vnr can be used. A Vnr can therefore be unlocked or locked. Unlocked The Vnr can be used for the same article in any Nordic country, as long as the criteria for using the same Vnr in several countries are met. This means that the Vnr will automatically be allocated to a new country when a Vnr is applied for with the same article information. Unlocked is the default setting. Locked The Vnr can only be used in the specified country/countries. This means that a new Vnr will be allocated to a new country when a Vnr is applied for with the same article information. If a Vnr is locked and it is desired to use the locked Vnr in another country, the holder of the Vnr in the country/countries, where the Vnr is locked, must approve the usage in the additional country in advance. It is the responsibility of the company to specifically confirm that the unlocking in the original country/countries can be performed. When applying for a Vnr the applicant must select whether the Vnr should be unlocked or locked. Unlocked is the default setting. Version: 1.7 8/23

4 Vnr status administration An article can have three different statuses in the Vnr system: Assigned On market Withdrawn In order for NNC to take correct decisions it is important that the status of an article in each country is correct in the Vnr system. It is therefore the responsibility of the company to inform NNC about changes in the status of an article for each country. Note that the status of a Vnr can vary between countries. 4.1 Assigned Assigned is the status of an article, which not yet has been marketed. Normally this status should only be used for a short period of time, since Vnrs should be applied for when the marketing authorisation holder knows which packages will be marketed and really need Vnrs. Since articles with the status Assigned have never been on the market, it is easier to change the information of these articles than for articles, which have been on the market. When an article is to be marketed the status must be changed to On market. An article may not be marketed in a country where its Vnr has the status Assigned. 4.2 On market When an article is marketed in a country, the status of the Vnr is On market. NOTE - When an article has been launched on the market it is difficult to change the information without changing the Vnr. This is also true if an article has been on the market in another Nordic country with the same Vnr. 4.3 Withdrawn A Vnr can have the status Withdrawn in one or several countries. It is absolutely forbidden to reuse a withdrawn Vnr for another article. In some cases NNC may reactivate a withdrawn Vnr if the article is exactly the same and if all the information is still relevant. This can only take place after direct contact with, and decision by, NNC. Version: 1.7 9/23

5 Criteria for Nordic Article Number (Vnr) A Nordic Article Number can be approved to cover one, several, or even all Nordic countries. Six basic criteria are mandatory and need to be met equally in all countries concerned if a Vnr is to be used in more than one country. Trade name Marketing authorisation holder (MAH) Pharmaceutical dosage form Strength Pack size Type of package 5.1 Trade name The trade name of the article must be exactly the same in all countries where a Vnr will be used. Even small differences in trade name are not permitted. For example: Alvedon vs. Alvedone 5.2 Marketing authorisation holder (MAH) The marketing authorisation holder does not necessarily have to be the same in all concerned countries where a Vnr is used, but the MAH must belong to the same group of companies (same consolidated corporation) or be an official representative for the MAH. For example: Group of companies: Company group name MAH: Denmark: Company name A/S Finland: Iceland: Norway: Sweden: Company name Oy Company name hf Company name AS Company name AB Version: 1.7 10/23

5.3 Pharmaceutical dosage form The pharmaceutical dosage form must be the same in all concerned Nordic countries where the same Vnr is used. However, linguistic differences in presenting the pharmaceutical dosage form can be approved as long as the composition of the product is the same and the term used complies with the EU Standard Terms. For example: European standard term: Tablet Danish: Tablet Finnish: Tabletti Icelandic: Tafla Norwegian: Tablett Swedish: Tablett This means, for example, that it is not permitted to use the same Nordic Article Number for tablets in one country and capsules in another, or tablet in one country and film coated tablet in another. 5.4 Strength The strength must be the same in all concerned Nordic countries where the same Vnr is used. However, some differences in presenting the strength might be approved after discussion with NNC. 5.5 Pack size The pack size must be the same in all Nordic countries where the same Vnr is used for an article, for instance number of tablets or ml. 5.6 Type of package The type of package must be the same in all Nordic countries where the same Vnr is used for an article, for instance blister, jar or bottle. The package material must also be the same in all countries. It is not allowed to have a glass jar in one country and a plastic jar in another, or a glass vial in one country and a plastic vial in another. 5.7 Package appearance and/or package information leaflet If the six criteria above are fully met, but the text on the package and/or the appearance of the package and/or the package information leaflet differs within the Nordic countries, an unlocked common Vnr can still be approved. However, in this case the packages with the same Vnr should be separated with different GTINs. Version: 1.7 11/23

Version: 1.7 12/23

6 Impact on Vnr when an article and/or package is changed NOTE - All changes of an article and its package must be informed to, and confirmed with, NNC/PIC in advance. The general rule is that the Vnr must be changed if any of the six basic criteria described in chapter 5 has been changed, or no longer is valid. In many cases it is not mandatory, but most often recommended, to change the Vnr, since it thereby will be obvious to all stakeholders that the article somehow has been changed. Changes can easily be made for Vnrs, which never have been on the market (status Assigned) in any country. Only in very special cases and rarely can a Vnr be kept when an article or its package, which has been on a market, is changed. Usually a new Vnr is required. It is absolutely forbidden to reuse a withdrawn Vnr for another article. In some cases NNC may reactivate a withdrawn Vnr if the article is exactly the same and if all the information is still relevant. This can only take place after direct contact with, and decision by, NNC. In order for NNC to take correct decisions it is important that the status of an article in each country is correct in the Vnr system. It is therefore the responsibility of the company to inform NNC about changes in the status of an article for each country. 6.1 Introduction of a new pharmaceutical product to the market Nordic Article Numbers should be applied for as close to the marketing authorisation as possible. If the article already has a Vnr NNC still must be informed before the introduction of the article to the market. For further information, see chapter 3 Application for Nordic Article Number. 6.2 Change in the composition of the article If the active substance of a product is altered in any way, a new Nordic Article Number must be assigned to the article. If the change only concerns an excipient, the Vnr does not need to be changed. However, the Vnr may be changed to mark that the article has been changed. Please contact NNC to discuss the specific situation. Version: 1.7 13/23

6.3 Change of trade name It is recommended that the Vnr is changed when the trade name of the product changes. If agreed upon in advance with NNC the Vnr, in certain situations, can be maintained: The article only exists in one country The trade name change takes place more or less at the same time (within a few months) in all Nordic countries. If it takes longer the Vnr must be changed. Note that the instructions for Denmark differs from the other Nordic countries, see chapter 10.1.1 Denmark. Note that there, for some countries, may be further country specific guidelines. 6.4 Change of marketing authorisation holder (MAH) The same Vnr can be maintained if the MAH is changed at the same time in all Nordic countries and if the old and the new MAH agree on this. It should be noticed, that the sales statistical history moves to the new MAH together with the Vnr. When a product changes MAH all other but withdrawn Vnrs associated with the product must be moved to the new MAH. Thereafter the Vnrs can be continuously used or changed. The status of not needed Vnrs may be changed to Withdrawn, but the Vnrs must not be directly deleted from the national product and article registers. Please contact NNC to discuss the specific situation. Note that there, for some countries, may be further country specific guidelines. 6.5 Change of the marketer If all other article information remains the same, the same Vnr can be maintained. However, NNC must be informed about changes in marketer in advance. Please note that Vnrs are found in the Vnr extranet service under marketer companies, but Vnrs belong to the MAH. Version: 1.7 14/23

6.6 Change of pharmaceutical dosage form NNC must be informed about all changes of the pharmaceutical dosage form. Linguistic differences in presenting the pharmaceutical dosage form can be approved as long as the composition of the product is the same and the term used complies with the EU Standard Terms, see chapter 5.3 Pharmaceutical dosage form. However, NNC must be informed in advance for confirmation. 6.7 Change of strength A change in strength always results in a new article that needs a new Vnr, see chapter 5.4 Strength. 6.8 Change of pack size The pack size must be the same in all concerned Nordic countries where the same Vnr is used, for instance number of tablets or ml. 6.9 Change of package type In most cases the Vnr needs to be changed. Please contact NNC for further information, when considering changing package type or package material. Note that there, for some countries, may be further country specific guidelines. 6.10 Change of Rx / OTC An OTC-package is by definition a different package compared to the corresponding Rx-package and must therefore carry different Vnrs if both packages are on the market at the same time. 6.10.1 Switch Rx -> OTC If a switch is made from RX to OTC the Vnr should be changed, since the requirements for package text, package leaflet etc. differ. 6.10.2 Switch OTC -> Rx If a switch is made from OTC to Rx the Vnr can be maintained. Note that the instructions for Norway differs from the other Nordic countries, see chapter 10.2 Norway. Version: 1.7 15/23

6.11 Withdrawal of a Vnr A Vnr can have the status Withdrawn in one or several countries. It is absolutely forbidden to reuse a withdrawn Vnr. Companies can notify Vnr withdrawals at any time by using the withdrawal function in the Vnr extranet service. Note that there, for some countries, may be further country specific guidelines. Version: 1.7 16/23

7 Frequently Asked Questions 7.1 May a Vnr, if it is already in use in one or several other Nordic countries, automatically be taken into use in another country? No, NNC must confirm that the Vnr can be used in a new country. In order for a Nordic Article Number to be used in several countries the article must meet the six basic criteria, see chapter 5 Criteria for Nordic Article Number. A Vnr can be unlocked or locked. If the Vnr is unlocked the Vnr will automatically be allocated to a new country when a Vnr is applied for with the same article information. If a Vnr is locked and it is desired to use the locked Vnr in another country, the holder of the Vnr in the country/countries, where the Vnr is locked, must approve the usage in the additional country in advance. 7.2 May a medical device have a Nordic Article Number? A medical device cannot have a Vnr, as they are only used for pharmaceutical products. However, medical devices can have National article numbers. Note that there, for some countries, may be further country specific guidelines. 7.3 May a compounded drug provided under special licence have a Vnr? An article without marketing authorisation cannot have a Nordic Article Number. However, a compounded drug provided under special licence and extemporaneous preparations can have a National article number. Note that there, for some countries, may be further country specific guidelines. 7.4 May an identical parallel imported article originating from different export countries have the same Vnr in a country and in different countries? Identical parallel imported pharmaceuticals originating from different export countries should have the same Nordic Article Number in a country. If they fulfil the conditions for common Nordic packs they could have the same Vnr in the different Nordic countries despite differing MT-numbers. 7.5 Transport packages and primary packages The labelling of transport packages and primary packages falls outside the rules relating to Vnrs. Version: 1.7 17/23

8 Barcode It is not mandatory, but highly recommended, that all pharmaceutical packages with a marketing authorisation should have a machine-readable barcode printed on the package. The standard of the barcode on pharmaceuticals in the Nordic countries is EAN, which contains an identification number on the format GTIN (changed names from EAN in 2003). 8.1 Format of the barcode The format of the barcode should be EAN-13, or where this is not possible EAN-8, i.e. the package is so small that there is not enough space for an EAN-13 barcode. When it was decided that a barcode should be printed on all pharmaceutical packages in the 1980 s, the Vnr was central and dispensing was still handled manually. It was therefore argued that it was important that the Vnr should be included in the new identification code represented by the barcode. In order to achieve this it was decided that pharmaceuticals in the Nordic countries should have modified formats of GTIN-13 and GTIN-8. This format was named NTIN. However, the prerequisite that the barcode should include a Vnr is no longer valid from a logistical point of view. This means that the GTIN-13 and GTIN-8 formats of the barcode currently can be GTIN or NTIN. 8.1.1 GTIN A GTIN-13 consists of 13 digits on the format: Company s prefix + article reference number + check digit A GTIN-8 consists of 8 digits on the format: 7 3 X X X X S C 73XXXX GS1-8-prefix a six-digit company prefix allocated by GS1 S one digit article reference number allocated by the company (1,2,3 0) This means that GTIN-8 can be used to number up to 10 packages. C Check digit calculated in accordance with a GS1 algorithm For more information regarding GTINs, please see the local GS1 webpages Denmark: www.gs1.dk Finland: www.gs1.fi Iceland: www.gs1.is Norway: www.gs1.no Sweden: www.gs1.se Version: 1.7 18/23

8.1.2 NTIN An NTIN-13 has the same format as a GTIN-13, i.e. 13 digits, but with a fixed prefix and a Vnr instead of an article reference number. Prefix of Nordic Number Centre (704626) + Vnr + check digit 704626 is the prefix of NNC used as a common Nordic company prefix for pharmaceuticals. An NTIN-8 has the format: 2 + Vnr + check digit Please note that there is a theoretical risk of mix-ups with articles other than pharmaceuticals. To reduce this risk NTIN-8 should only be used on prescription medicines. NTINs can only be acquired from NNC by using the Vnr extranet service: https://vnr.fi. A confirmed barcode will then be visible in the detailed Vnr information section, for more information please contact NNC. 8.2 Transfer from NTIN to GTIN Since NTIN contains the Vnr, there can be only one NTIN per Vnr. The barcode will thereby be the same for all packages with the same Vnr, making it impossible to uniquely identify the different packages of an article. A GTIN identifies a unique package. An NTIN identifies a unique package only if the article has only one package. Otherwise NTIN identifies the article, as the Vnr is a part of the NTIN format. The European directive on falsified medicines prescribes mandatory, harmonised safety features on all prescription pharmaceuticals. These safety features will consist of a unique package identity combined with tamper evidence. Only unique NTINs or GTINs should be used as barcodes. For more information on GTINs, please see http://wiki.vnr.fi/?page_id=1671. Version: 1.7 19/23

9 Multi packages There are two kinds of multi packages. 9.1 The single packages of a multi package have market authorisation A registered multi package can contain units with marketing authorisation as separate packages, e.g. 10x100 tablets. The single packages within a multi package may have the same Vnr (Vnr XX XX XX) as the registered separate single packages on the market. The Vnr of the multi package (Vnr YY YY YY) must differ, and may not appear on the single packages inside. Note that the instructions for Denmark differs from the other Nordic countries, see chapter 10.1.3 Denmark. Vnr xx xx xx Vnr xx xx xx Vnr YY YY YY 9.2 Only the multi package has a market authorisation A registered multi package can contain units, without market authorisation. In this case the single packages must not have a Vnr, but the multi package must have a Vnr number (Vnr YY YY YY). Vnr YY YY YY Version: 1.7 20/23

10 Differences between the Nordic countries regarding Vnr 10.1 Denmark 10.1.1 Change of trade name A new Vnr must always be applied for when the trade name of the product changes. 10.2 Norway 10.2.1 Change of Rx / OTC In Norway the general view is that a Rx- and an OTC-pack always should carry different Vnrs regardless of the direction of the switch (Rx/OTC or OTC/Rx). 11 Pricing of Nordic Article Numbers The cost for NNC is divided between the Nordic countries. Each country decides how to cover its cost. Therefore the charges for Vnrs may differ between Nordic counties. For more information please contact NNC. 12 Contact information The administration of the Vnr system is under responsibility of the Nordic Number Centre (NNC) 2, located at Pharmaceutical Information Centre Ltd (PIC) (Lääketietokeskus Oy), Helsinki, Finland. vnr@vnr.fi 12.1 Denmark Dansk Lægemiddel Information A/S Strødamvej 50 A 2100 København Ø Tel. +45 39 27 44 88 E-mail: dli@dli.dk www.dli.dk 2 On behalf of the Nordic country organisations Dansk Lægemiddel Information A/S in Denmark, Pharmaceutical Information Centre Ltd in Finland, The Icelandic Federation of Trade, Legemiddelindustriforeningen in Norway, and Läkemedelsindustriföreningens Service AB, LIF, in Sweden. Version: 1.7 21/23

12.2 Finland Pharmaceutical Information Centre Ltd Korkeavuorenkatu 35 00130 Helsinki FINLAND Tel. +358 9 6150 4950 Fax. +358 9 6150 4941 E-mail: vnr@vnr.fi www.laaketietokeskus.fi 12.3 Iceland The Icelandic Federation of Trade Hus verslunarinnar Kringlan 7 103 Reykjavík, Iceland E-mail: ift@ift.is Website: www.ift.is 12.4 Norway Legemiddelindustriforeningen Postboks 5094 Majorstuen NO-0301 Oslo Tel. +47 23 16 15 00 E-mail: lmi@lmi.no www.lmi.no 12.5 Sweden Läkemedelsindustriföreningens Service AB, LIF Box 17608 118 92 Stockholm Tel: +46 8 462 37 00 E-mail: info@lif.se www.lif.se Any questions about Vnrs and National article numbers in Sweden can be directed to ehälsomyndigheten: registrator@ehalsomyndigheten.se Version: 1.7 22/23

13 Definitions GS1 GS1 is an international not-for-profit association with member organisations in over 100 countries. The GS1 standards, e.g. GTIN, are the most widely used supply chain standards in the world. www.gs1.se or www.gs1.com GTIN MAH Marketer National article number NNC Nordic Article Number NTIN OTC PIC Rx Global Trade Item Number a global standard for article numbering administered by GS1. Consists of 13, maximum 14, digits on the format company s prefix + article reference number + check digit. Can be presented in a barcode for automatic reading. Marketing Authorisation Holder Company that represents the product (often the same as MAH) A six-digit code (200000-369999 and 600000-999999) used in the pharmacies for articles, which are not human or veterinary medicines. The same article number can be used for different articles in different Nordic countries. The administration of the Vnr system is under responsibility of the Nordic Number Centre (NNC), located at Pharmaceutical Information Centre Ltd (PIC) (Lääketietokeskus Oy), Helsinki, Finland. vnr@vnr.fi Vnr a six-digit identification code (000001-199999 and 370000-599999) for a specific article of medicine with marketing authorisation in the Nordic countries. A Vnr is given to all human and veterinary medicines. It enables a simple verification of articles at all distribution stages. National/Nordic Trade Item Number Used instead of GTIN for pharmaceuticals in the Nordic countries. Same format as GTIN (13, maximum 14, digits) but with a fixed prefix and a Vnr instead of an article reference number. Format: prefix of Nordic Number Centre (704626) + Vnr + check digit Pharmaceuticals available without a prescription. Pharmaceutical Information Centre http://www.laaketietokeskus.fi/en Pharmaceuticals only available with a prescription Vnr Nordic Article Number a six-digit identification code (000001-199999 and 370000-599999) for a specific article of medicine with marketing authorisation in the Nordic countries. A Vnr is given to all human and veterinary medicines. It enables a simple verification of articles at all distribution stages. Version: 1.7 23/23